AVITA Medical

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Munich,,Bavaria,,Germany,-,March,31,2023:,Avita,Medical,Develops

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

RCEL

AVITA Medical revises 2024 revenue guidance to $64.3 million, citing year-end inventory adjustments, and forecasts 2025 revenue growth of 55%-65% with new product launches.

Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals

movers image

Pre-Market Outlook

Markets

FUBO

IONQ

LAES

QBTS

QUBT

RGTI

AVITA Medical, Quantum Computing And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

ServiceNow

Initiation

Analyst Ratings

MREO

This ServiceNow Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

AVITA Medical Inc

Press Releases

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

AVITA Medical to Host Investor Webinar Briefing

AVITA Medical to Present at TD Cowen's 45ᵗʰ Annual Health Care Conference

AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

AVITA Medical to Announce First Quarter 2025 Financial Results

Abeona Therapeutics

Astria Therapeutics

aTyr Pharma

Aura Biosciences

Candel Therapeutics

Cidara Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Humacyte

Immutep Limited - American Depositary Shares

Immutep

ITeos Therapeutics

Monopar Therapeutics

Nuvectis Pharma

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Acelyrin

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

2seventy bio

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Verastem

XOMA Royalty

D. Boral Capital

Lake Street

Cantor Fitzgerald

Piper Sandler

B of A Securities

Comments

AVITA Medical

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell